ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the LOTIS-7 Phase 1b open-label ...

BOSTON--(BUSINESS WIRE)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel ...

Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within the ...

XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the ...

MONTREAL, Oct. 21, 2024 /CNW/ - AbbVie (ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or ...

—Adding data on lymphoma in adolescents and young adults may help improve the standardization of treatment and improve patient outcomes. Although cancer in adolescents and young adults (AYAs) is ...

Kami Maddocks, MD, advises early-career physicians on diffuse large B-cell lymphoma, emphasizing the disease's heterogeneity and the importance of considering patient characteristics, pathological ...

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous and aggressive form of non-Hodgkin lymphoma, with a standard treatment approach typically involving R-CHOP. Despite overall favourable ...

Shares of ADC Therapeutics fell after it reported the death of two patients in a late-stage trial for treating an aggressive cancer that starts in white blood cells. The stock fell 7.6% to $4.25 in ...

Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...

LAS VEGAS, Aug. 27, 2025 /PRNewswire/ -- DelveInsight's Diffuse Large B-cell Lymphoma Market Insights report includes a comprehensive understanding of current treatment practices, diffuse large B-cell ...